	US 11,883,464 B2
	Nerve growth factor fusion protein, preparation method and use thereof
Qingshuang Zhang, Beijing (CN); Lei Ma, Beijing (CN); and Ming Liu, Beijing (CN)
Assigned to Staidson (Beijing) Biopharmaceuticals Co., Ltd., Beijing (CN)
Appl. No. 16/085,984
Filed by Staidson (Beijing) Biopharmaceuticals Co., Ltd., Beijing (CN)
PCT Filed Mar. 17, 2017, PCT No. PCT/CN2017/077025 § 371(c)(1), (2) Date Sep. 17, 2018, PCT Pub. No. WO2017/157325, PCT Pub. Date Sep. 21, 2017.
Claims priority of application No. 201610159303.7 (CN), filed on Mar. 18, 2016.
Prior Publication US 2020/0331977 A1, Oct. 22, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/48 (2006.01); A61K 38/00 (2006.01); A61P 25/00 (2006.01); A61K 38/18 (2006.01); C12N 15/85 (2006.01)

CPC A61K 38/18 (2013.01) [A61K 38/185 (2013.01); A61P 25/00 (2018.01); C07K 14/48 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

9 Claims

1. A nerve growth factor fusion protein, comprising a general formula A-B or A-L-B, wherein:

A is a human nerve growth factor,

L is a linker peptide, and

B is an Fc moiety of IgG1, a mutant of the Fc moiety of IgG1, or a fragment of the Fc moiety of IgG1, wherein the mutant of the Fc moiety comprises a site mutation associated with antibody dependent cell-mediated cytotoxicity (ADCC)/complement dependent cytotoxicity (CDC) activity, or a deglycosylation mutation;

wherein the human nerve growth factor comprises F12E with reference to the amino acid position set forth in mature wild-type human nerve growth factor.